AN2 Therapeutics Initiates Pivotal Phase II/III Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

AN2 Therapeutics, Inc. announced it has screened its first patient in its pivotal Phase II/III clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common form of nontuberculous mycobacterial lung disease.